Tezepelumab 治疗中重度至极重度慢阻肺的 2a 期 COURSE 试验
COURSE 是一项双盲随机安慰剂对照 2a 期试验,纳入 333 例接受三联吸入治疗的中重度至极重度慢阻肺患者,比较 tezepelumab 420 mg 每 4 周皮下注射与安慰剂共 52 周。预设亚组中基线血嗜酸性粒细胞≥150 cells/μL 者显示数值上更低的加重率。安全性良好。
要点
- 预设亚组中基线 BEC≥150 cells/μL 患者 tezepelumab 加重率数值更低,但置信区间跨 1。
- 安全性可接受:不良事件 81% vs 75%,严重不良事件两组均 30%,无治疗相关死亡。
核心结论
- Tezepelumab 未显著降低中重度至极重度慢阻肺患者的年化中重度急性加重率。
- Tezepelumab 耐受性良好,未发现新的安全性问题。
- 需进一步研究评估 tezepelumab 在基线 BEC≥150 cells/μL 患者中的疗效。
研究设计与样本
- COURSE 为双盲、随机、安慰剂对照 2a 期试验,在亚洲、欧洲和北美 10 国 90 个中心开展。
- 纳入 40-80 岁、中重度至极重度气流受限、接受三联吸入维持治疗且入组前 12 个月至少 2 次中重度急性加重的患者。
- 333 例患者按 1:1 随机接受 tezepelumab 420 mg(n=165)或安慰剂(n=168)皮下注射,每 4 周一次,最长 52 周。
- 随机按地理区域和入组前 12 个月急性加重次数分层。
- 主要终点为 52 周年化中重度慢阻肺急性加重率;预设亚组按基线血嗜酸性粒细胞计数(BEC)分析。
主要发现
- 不良事件发生率 tezepelumab 组 133/165(81%)vs 安慰剂组 126/168(75%);严重不良事件两组均为 30%(49 例 vs 50 例);治疗期间死亡 5 例(tezepelumab 组 2 例、安慰剂组 3 例),研究者评估均与治疗无因果关系。
临床怎么用
- 目前证据不支持在未筛选的中重度至极重度慢阻肺患者中常规使用 tezepelumab 预防急性加重。
- 对基线血嗜酸性粒细胞≥150 cells/μL 的患者,tezepelumab 显示出数值上更低的加重率,但置信区间跨 1,需进一步研究验证。
- Tezepelumab 在该人群中的安全性可接受,未发现新的安全信号。
局限性
- 主要终点未达到统计学显著性,亚组分析结果仅为探索性,不能作为疗效结论。
- 研究为 2a 期试验,样本量 333 例,可能不足以检测较小效应。
- 亚组置信区间均较宽且跨 1,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with healthy individuals. We aimed to assess the efficacy and safety of tezepelumab in patients with moderate to very severe COPD despite receiving triple inhaled therapy. METHODS: COURSE was a double-blind, randomised, placebo-controlled, phase 2a trial across 90 sites in ten countries in Asia, Europe, and North America. Eligible participants were aged 40-80 years, had moderate to very severe airflow limitation, were receiving triple inhaled maintenance therapy, and had at least two moderate to severe COPD exacerbations in the 12 months before enrolment. Patients were randomly assigned (1:1) to receive tezepelumab 420 mg or placebo subcutaneously every 4 weeks for up to 52 weeks. Randomisation was stratified by geographical region and by number of exacerbations in the 12 months before enrolment. Participants, investigators, site staff, and the study sponsor were masked to treatment assignment. The primary endpoint was the annualised rate of moderate or severe COPD exacerbations over 52 weeks. A prespecified subgroup analysis assessed the primary endpoint in patients grouped by baseline blood eosinophil counts (BECs). Efficacy and safety were assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04039113 (completed). FINDINGS: Between July 30, 2019, and Oct 4, 2022, 333 patients (mean age 67·2 years [SD 7·0]; 145 [44%] female and 188 [56%] male; 293 [88%] White, 34 [10%] Asian, and four [1%] Black or African American) were randomly assigned and treated with tezepelumab (n=165) or placebo (n=168). The annualised rate of moderate or severe COPD exacerbations over 52 weeks was 1·75 for tezepelumab versus 2·11 for placebo (rate ratio 0·83 [90% CI 0·64-1·06]; p=0·10 [one-sided]; the primary endpoint was not met). In prespecified subgroup analyses, the annualised rate of moderate or severe COPD exacerbations over 52 weeks was 2·04 with tezepelumab versus 1·71 with placebo (rate ratio 1·19 [95% CI 0·75-1·90]) in patients with a baseline BEC of less than 150 cells per μL, 1·64 versus 2·47 (0·66 [0·42-1·04]) in patients with a baseline BEC of 150 cells per μL to less than 300 cells per μL, and 1·20 versus 2·24 (0·54 [0·25-1·15]) in patients with a baseline BEC of 300 cells per μL or higher. Adverse events occurred in 133 (81%) of 165 patients in the tezepelumab group and 126 (75%) of 168 patients in the placebo group. Serious adverse events occurred in 49 (30%) patients in the tezepelumab group and 50 (30%) patients in the placebo group. Five patients died while receiving study treatment: two in the tezepelumab group and three in the placebo group. No deaths were determined to be causally related to study treatment by investigator assessment. INTERPRETATION: A significant reduction was not observed in the annualised rate of moderate or severe COPD exacerbations with tezepelumab versus placebo. Further studies are required to evaluate the efficacy of tezepelumab in patients with moderate to very severe COPD, particularly in patients with a baseline BEC of 150 cells per μL or higher. Tezepelumab was well tolerated, with no safety concerns identified. FUNDING: AstraZeneca and Amgen.
引用
- Singh D, Brightling CE, Rabe KF, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2024. PMID: 39653044. doi:10.1016/S2213-2600(24)00324-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。